TransMedics, a medical technology company, reported significant financial results, beating earnings per share (EPS) and revenue expectations for the fourth quarter and full year of 2023, and increased its share count by +43%. The company also provided a fiscal year 2024 guidance that exceeded consensus expectations, leading to a 10.6% increase in its stock price after hours (AH) and was up +17.1% pre-market following the announcement. The positive financial performance and optimistic future guidance have sparked discussions about TransMedics' potential growth, with predictions that it could become a $10B+ company.